Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) Enterprise Value: 2020-2025

Historic Enterprise Value for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to $2.1 billion.

  • Arcutis Biotherapeutics' Enterprise Value rose 173.51% to $2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 615.65%. This contributed to the annual value of $1.2 billion for FY2024, which is 3596.02% up from last year.
  • Arcutis Biotherapeutics' Enterprise Value amounted to $2.1 billion in Q3 2025, which was up 39.77% from $1.5 billion recorded in Q2 2025.
  • Arcutis Biotherapeutics' 5-year Enterprise Value high stood at $2.1 billion for Q3 2025, and its period low was $33.0 million during Q4 2023.
  • Over the past 3 years, Arcutis Biotherapeutics' median Enterprise Value value was $714.2 million (recorded in 2024), while the average stood at $861.9 million.
  • As far as peak fluctuations go, Arcutis Biotherapeutics' Enterprise Value plummeted by 93.30% in 2023, and later spiked by 3,596.02% in 2024.
  • Arcutis Biotherapeutics' Enterprise Value (Quarterly) stood at $656.1 million in 2021, then declined by 24.99% to $492.1 million in 2022, then slumped by 93.30% to $33.0 million in 2023, then spiked by 3,596.02% to $1.2 billion in 2024, then soared by 173.51% to $2.1 billion in 2025.
  • Its Enterprise Value stands at $2.1 billion for Q3 2025, versus $1.5 billion for Q2 2025 and $1.7 billion for Q1 2025.